



CIN: L24100GJ1984PLC111413

Reg. Office: 1-5th Floor, Aditraj Arcade, Nr Karma Shreshtha Tower, 100 Ft Rd, Satellite, Ahmedabad - 380015.

Date: 14th November, 2025

To,

Listing Compliances, BSE Limited, P. J. Towers, Fort, Mumbai - 400001. Scrip Code: 539938; Scrip Id: MIL	Listing Compliances, CSE - India, 7, Lyons Range, Dalhousie Kolkata - 700001.
--	---

Subject: Outcome of Board Meeting and Compliances of Regulation 30 and 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Dear Sir/Ma'am,

Pursuant to provisions of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e., November 14, 2025, inter alia, considered and approved Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended on September 30, 2025 along with Limited review report issued by M/s. V Goswami & Co, Statutory Auditors of the Company.

Further, please find enclosed "Standalone and Consolidated unaudited Financial Results along with Limited Review Report" for the quarter and half year ended on September 30, 2025 as **Annexure 1** and same is also available on the website of the Company viz. www.medicointercontinental.com

The Board Meeting of the Company commenced at 12:30 PM and concluded at 06:00 PM.

This is for your information and records.

Thanking You,

FOR MEDICO INTERCONTINENTAL LIMITED



Samir D Shah
Managing Director
(DIN: 03350268)



V. GOSWAMI & CO.

CHARTERED ACCOUNTANTS

RBI UCN NO. :- 897783
C&AG REG NO. :- WR4659
MSME :- GJ01D0134595
GST :- 24AAHFV3075F1Z7

3, SF, Manek Appt, Nr. Jain Derasar, B/s. Tagor Park, Nehrunagar Circle, Ahmedabad - 380015.
M : 910721728711 E-mail: thegoswami@gmail.com, www.goswami.in
Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended)

TO THE BOARD OF DIRECTORS OF MEDICO INTERCONTINENTAL LIMITED


We have reviewed the accompanying Statements of Standalone Unaudited Financial Results of MEDICO INTERCONTINENTAL LIMITED ("the company"), for the quarter ended September 30, 2025 ("the Statement") and year to date from April 01, 2025 to September 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, V. GOSWAMI & CO,
Chartered Accountants
(FRN: 0128769W)


Vipul Goswami
(Partner)



Mem. No: 119809

Date: - 14/11/2025

Place:-Ahmedabad

UDIN: 25119809BMLIVM8761



MEDICO INTERCONTINENTAL LIMITED						
CIN NO: L24100GJ1984PLC111413						
Regd. Off: 1-5th FLOOR, ADIT RAJ ARCADE NR KARMA, SHRESHTHA TOWER, 100 FT RD, SATELLITE, AHMEDABAD - 380015, GUJARAT IN						
Tel No. 079-26742739 E-mail:- mail@medicointercontinental.com Website: www.medicointercontinental.com						
Statement of Standalone Unaudited Financial Results for the Quarter and Half year ended September 30, 2025						
(Rs. in Lakhs)						
Sr. No.	Particulars	Quarter Ended			Half Year Ended	
		3 Months ended	Preceding 3 Months ended	Corresponding 3 months ended in previous year on	Year to date figure for current period ended	Year to date figure for previous period ended
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	31.03.2025
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenues					
1	Revenue from Operations	1241.95	1346.68	2893.73	2588.62	6712.98
2	Other Income	58.05	24.19	9.79	82.24	50.77
3	Total Revenue (A)	1300.00	1370.86	2903.51	2670.86	6763.75
4	Expenses					
(a)	Cost of materials consumed	0.00	0.000	0.00	0.00	0.00
(b)	Purchases of stock-in-trade	1029.78	947.94	2136.24	1977.72	5444.92
(c)	Changes in inventories of finished goods and stock-in-trade	12.96	128.51	212.33	141.47	162.74
(d)	Employee benefits expense	56.13	50.88	37.45	107.01	174.06
(e)	Finance costs	44.90	43.52	17.88	88.42	67.22
(f)	Depreciation and amortisation expense	18.71	17.56	14.74	36.28	55.57
(g)	Other expenses	56.99	108.76	340.35	165.75	501.68
	Total Expenses (B)	1219.46	1297.18	2758.99	2516.64	6406.20
5	Profit/(Loss) before exceptional items & tax (1-4)	80.54	73.68	144.53	154.22	357.55
6	Exceptional items	0.00	0.00	0.00	0.00	0.00
7	Profit/(Loss) for the period from operations before tax (5+6)	80.54	73.68	144.53	154.22	357.55
8	Tax expense	21.35	18.08	45.63	39.42	100.97
(a)	Current Tax	21.53	19.71	39.10	41.24	94.44
(b)	Deferred Tax	-0.18	-1.63	6.53	-1.82	6.54
9	Profit/(Loss) for the period from continuing operations (7-8)	59.19	55.60	98.89	114.80	256.58
10	Profit/(Loss) for the period from discontinued operations	0.00	0.00	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00
12	Profit/(loss) for the period from Discontinued operations (after tax)	0.00	0.00	0.00	0.00	0.00
13	Profit/ (loss) for the period (After tax)	59.19	55.60	98.89	114.80	256.58
14	Other Comprehensive Income					
	Other comprehensive Income/(Loss)	0.00	0.00	0.00	0.00	0.00
15	Total Comprehensive Income for the period (13+14)	59.19	55.60	98.89	114.80	256.58
	Paid-up Equity Share Capital (Face Value INR 10 each)	1000.00	1000.00	1000.00	1000.00	1000.00
16	Earnings Per Equity Share of Rs. 10 each (for continuing Operations)					
(a)	Basic - INR	0.59	0.56	0.99	1.15	2.57
(b)	Diluted - INR	0.59	0.56	0.99	1.15	2.57
17	Earnings Per Equity Share of Rs. 10 each (for discontinuing Operations)					
(a)	Basic - INR	0.00	0.00	0.00	0.00	0.000
(b)	Diluted - INR	0.00	0.00	0.00	0.00	0.000
18	Earnings Per Equity Share of Rs. 10 each (for continuing & discontinuing Operations)					
(a)	Basic - INR	0.59	0.56	0.99	1.15	2.57
(b)	Diluted - INR	0.59	0.56	0.99	1.15	2.57
<p>1. The above unaudited standalone financial results of the Company for the quarter and half year ended September 30,2025 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 14, 2025. The above results are reviewed by statutory auditors and who have expressed an unmodified opinion on these results.</p> <p>2. These results have been prepared in accordance with the Ind AS notified under the Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.</p> <p>3. During the quarter ended September 30, 2025, the company is operating in single segment. So segment reporting is not applicable for this quarter, but segment information shall provides as and when the same shall be operative.</p> <p>4. The Company has continued with old Income Tax rates for the current quarter and is evaluating option available under section 115 BAA of the Income Tax Act, 1961 as per the Taxation Laws (Amendment) Ordinance, 2019.</p> <p>5. The previous period figures have been re-grouped / reclassified, wherever considered necessary.</p>						
Place:- Ahmedabad Date:-14/11/2025		<p>For and on behalf of Board of Directors of Medico Intercontinental Limited</p> <p> SAMIR SHAH MANAGING DIRECTOR DIN:03350268</p> 				

MEDICO INTERCONTINENTAL LIMITED
CIN: L24100GJ1984PLC111413

Regd. Off: 1-5th FLOOR, ADIT RAJ ARCADE NR KARMA, SHRESHTHA TOWER, 100 FT RD, SATELLITE, AHMEDABAD - 380015, GUJARAT IN

Tel No. 079-26742739

E-mail:- mail@medicointercontinental.com

Website: www.medicointercontinental.com

Unaudited Standalone Statement of Assets and Liabilities as at 30 September, 2025

(Rs in Lakhs)			
	Particulars	As at 30.09.2025 Unaudited	As at 31.03.2025 Audited
A. ASSETS			
1 Non-current assets			
Property, Plant and Equipments		145.13	167.93
Investment Property		294.11	271.00
Financial Assets			
(i) Investments		1,255.35	718.73
(ii) Loans		1,342.54	-
Deferred Tax Assets (Net)		2.78	0.97
Other Non-Current Assets		363.00	1,030.69
Total Non-Current Assets		3,402.92	2,189.32
2 Current assets			
Inventories		152.68	294.15
Financial Assets			
(i) Trade receivables		1,911.81	2,277.47
(ii) Cash and Cash Equivalents		147.23	141.77
(iii) Loans		-	100.80
Other Current Assets		12.54	873.62
Total Current Assets		2,224.25	3,687.81
TOTAL ASSETS		5,627.17	5,877.13
B. EQUITY AND LIABILITIES			
1 Equity			
Equity Share Capital		1,000.00	1,000.00
Other Equity		2,980.95	2,866.15
Total Equity		3,980.95	3,866.15
2 Non-Current Liabilities			
Financial Liabilities			
(i) Borrowings		1,310.49	1,277.05
(ii) Lease liability		-	29.32
(iii) Other financial liabilities		-	9.27
Long term provisions		11.84	-
Deferred tax liabilities (Net)		-	-
Other non-current liabilities		-	-
Total Non-Current Liabilities		1,322.33	1,315.64
3 Current Liabilities			
Financial Liabilities			
(i) Borrowings		61.14	44.53
(ii) Trade Payables		-	-
Due to Micro and Small Enterprises		97.97	132.67
Due to others		144.06	425.98
(iii) Other Financial Liabilities		-	-
Other Current Liabilities		2.79	67.11
Current tax liabilities (net)		17.94	24.47
Short term provisions		-	0.59
Total Current Liabilities		323.90	695.35
TOTAL EQUITY AND LIABILITIES		5,627.17	5,877.13
		0.00	0.00

For and on behalf of Board of Directors of
MEDICO INTERCONTINENTAL LIMITED

Place:- Ahmedabad
Date:- 14/11/2025

SAMIR SHAH
MANAGING DIRECTOR
DIN:03350268



MEDICO INTERCONTINENTAL LIMITED

CIN: L24100GJ1984PLC111413

Regd. Off: 1-5th FLOOR, ADIT RAJ ARCADE NR KARMA, SHRESHTHA TOWER, 100 FT RD, SATELLITE, AHMEDABAD - 380015, GUJARAT IN

Tel No. 079-26742739

E-mail:- mail@medicointercontinental.com

Website: www.medicointercontinental.com

Unaudited Standalone Cash Flow Statement for the half year ended 30 September, 2025

(Rs in Lakhs)

	PARTICULARS	Half year ended 30.09.2025 (Unaudited)	Half year ended 30.09.2024 (Unaudited)
A.	CASH FLOW FROM OPERATING ACTIVITIES :		
a)	Net Profit/ (Loss) before tax	154.22	212.92
b)	OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	154.22	212.92
	<u>Adjustments For:</u>		
	Depreciation	36.28	17.55
	Finance costs	88.42	27.37
	Profit on Sale of Asset	-14.62	0.00
	Interest and Dividend Income	-46.75	-10.79
	CASH GENERATED FROM OPERATIONS	217.55	247.05
	<u>Adjustments for</u>		
	Decrease/(Increase) in Inventories	141.47	260.35
	Decrease/(Increase) in Trade Receivables	365.66	-715.62
	Decrease/(Increase) in Other Current assets	861.08	7.99
	Increase/(Decrease) in Provisions	0.00	0.00
	Increase/(Decrease) in Trade Payables	-316.62	22.40
	Increase/(Decrease) in Current Financial Liabilities - Borrowings	0.00	0.00
	Increase/(Decrease) Non- Current Financial Liabilities	-29.32	0.00
	Increase/(Decrease) Current Financial Liabilities	0.00	0.00
	Increase/(Decrease) in Other Current Liabilities	-64.32	73.85
	CASH GENERATION FROM OPERATING ACTIVITY	1175.50	-103.98
	Income Tax Paid Net	(47.78)	(62.19)
	NET CASH FROM/(USED IN) OPERATING ACTIVITIES	1127.72	-166.16
B.	CASH FLOW FROM INVESTING ACTIVITIES:		
	Purchase of Fixed Assets	-3.48	-187.03
	Purchase of Investment Property	-198.00	0.00
	Decrease/(Increase) in Investment	-536.62	-162.03
	Sales Of Property	179.51	0.00
	Gratuity Expenses	1.99	1.10
	Interest and Dividend Income	46.75	10.79
	Other Non-Current Assets	667.70	0.00
	NET CASH FROM/(USED IN) INVESTING ACTIVITIES	157.85	-337.16
C.	CASH FLOW FROM FINANCING ACTIVITIES:		
	Proceeds from issue of Shares	-	-
	Increase/(Decrease) in Loans and Advances	-1241.74	-96.47
	Proceed from /(Repayment) of Borrowings net	33.44	610.67
	Proceed from /(Repayment) of Short Term Borrowings net	16.61	75.31
	Dividend Paid	0.00	0.00
	Finance Costs paid	-88.42	-27.37
	NET CASH FROM/(USED IN) FINANCING ACTIVITIES	-1280.12	562.14
	NET INCREASE IN CASH AND CASH EQUIVALENTS	5.45	58.81
	CASH AND CASH EQUIVALENTS (At the beginning of the year)	141.77	240.54
	CASH AND CASH EQUIVALENTS (At the end of the year)	147.23	299.35

For and on behalf of Board of Directors of
MEDICO INTERCONTINENTAL LIMITED

Place:- Ahmedabad

Date:- 14/11/2025


SAMIR SHAH
MANAGING DIRECTOR
DIN:03350268





V.GOSWAMI & CO.

CHARTERED ACCOUNTANTS

RBI UCN NO. :- 897783
C&AG REG NO. :- WR4659
MSME :- GJ01D0134595
GST :- 24AAHFV3075F1Z7

3, SF. Manak Apt. Nr. Jain Derasar, B/s. Tagor Park, Nehrunagar Circle, Ahmedabad - 380015.
M : +91 91287 23430, +91 97247 28711 | Email: thegoswami@gmail.com | www.goswami.in
Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated
Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 (as amended)

TO THE BOARD OF DIRECTORS OF MEDICO INTERCONTINENTAL LIMITED

We have reviewed the accompanying Statements of Consolidated Unaudited Financial Results of MEDICO INTERCONTINENTAL LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended September 30, 2025 ("the Statement") and year to date from April 01, 2025 to September 30, 2025 attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Parent Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement included the results of following subsidiary and joint venture company:-

1. EVAGRACE PHARMA PRIVATE LIMITED
2. RITZ FORMULATIONS PRIVATE LIMITED
3. SUNGRACE PHARMA PRIVATE LIMITED
4. AZILLIAN HEALTHCARE PRIVATE LIMITED
5. CALBORN LIFESCIENCE PRIVATE LIMITED
6. MEDICO LAB (Joint Venture)





V.GOSWAMI & CO.

CHARTERED ACCOUNTANTS

RBI UCN NO. :- 897783
C&AG REG NO. :- WR4659
MSME :- GJ01D0134595
GST :- 24AAHFV3075F1Z7

3, S.F. Manik Apt. No. Jain Derasar, B/s. Tagor Park, Nehrunagar Circle, Ahmedabad - 380015.
M : 91-9428733430, +91-9724728711 | E-mail : thegoswami@gmail.com | www.goswami.in

Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

During the quarter ended June 30, 2025, the Group has changed its accounting policy for investments in joint ventures (MEDICO LAB). Previously, the Group accounted for joint ventures using the proportionate consolidation method. Effective Q1 2025-26, the Group has adopted the equity method of accounting for investments in joint ventures, in accordance with Ind AS 28 "Investments in Associates and Joint Ventures."

The change in accounting policy has been applied retrospectively and the corresponding comparative figures for the previous periods have been restated to ensure comparability, as required under Ind AS 8 "Accounting Policies, Changes in Accounting Estimates and Errors."

A detailed reconciliation of the financial results previously reported under the proportionate consolidation method and the restated amounts under the equity method is provided in Note 4 to the consolidated results.

Our opinion is not modified in respect of these matters.

We did not review the interim financial results of the subsidiaries and joint venture included in the consolidated unaudited financial results, whose financial results and other unaudited financial information reflects total assets of Rs. 7209.83 Lakhs as at September 30, 2025, total revenues of Rs. 1267.91 Lakhs and Rs. 2332.64 Lakhs and total net profit Rs. (509.89) Lakhs and Rs.(814.29) Lakhs for quarter ended September 30, 2025 and for the period from April 01, 2025 to September 30, 2025, respectively, net cash inflow of Rs. 151.94 Lakhs for the period from April 01, 2025 to September 30, 2025, respectively as considered in the Statement whose financial results have not been reviewed by us. These interim financial results have been reviewed and certified by the Management of company whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiaries, is based solely on the reports of the Management and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of these matters.

For, V. GOSWAMI & CO,

Chartered Accountants

(FRN: 0128769W)

Vipul Goswami

(Partner)



Mem. No.: 119809

Date: 14/11/2025

Place: - Ahmedabad


UDIN: 25119809BMLIVN6736

MEDICO INTERCONTINENTAL LIMITED						
CIN NO: L24100GJ1984PLC111413						
Regd. Off: 1-5TH FLOOR, ADIT RAJ ARCADE NR KARMA SHRESHTHA TOWER, 100 FT RD, SATELLITE, Ahmedabad GJ 380015 IN						
Tel No. 079-26742739 E-mail:- mail@medicointercontinental.com Website: www.medicointercontinental.com						
Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year ended September 30, 2025						
(Rs In Lakhs)						
Sr. No.	Particulars	Quarter Ended			Half Year Ended	
		3 Months ended	Preceding 3 Months ended	Corresponding 3 months ended in previous year on	Year to date figure for current period ended	Year to date figure for previous period ended
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024
		Unaudited	Unaudited	Unaudited and Restated	Unaudited	Unaudited and Restated
						Previous Year ended
						Audited and Restated
	Revenues					
1	Revenue from Operations	2039.55	2135.49	3644.99	4175.04	5573.11
2	Other Income	55.41	26.30	6.05	81.72	17.25
3	Total Revenue (A)	2094.96	2161.79	3651.04	4256.75	5590.36
4	Expenses					
	(a) Cost of materials consumed	242.16	161.09	0.00	403.24	0.00
	(b) Purchases of stock-in-trade	1286.98	1288.59	2600.16	2575.57	3978.20
	(c) Changes in inventories of finished goods and stock-in-trade	146.46	158.57	226.81	305.03	378.86
	(d) Employee benefits expense	218.58	195.73	109.14	414.31	201.01
	(e) Finance costs	205.76	235.72	28.30	441.48	45.87
	(f) Depreciation and amortisation expense	195.41	61.87	20.06	257.28	28.23
	(g) Other expenses	234.14	264.37	437.97	498.51	580.62
	Total Expenses (B)	2529.49	2365.93	3422.43	4895.42	5212.80
5	Profit/(Loss) before exceptional items & tax (1-4)	-434.52	-204.14	228.61	-638.66	377.56
6	Exceptional Items	0.00	0.00	0.00	0.00	0.00
7	Profit/(Loss) for the period from operations before tax (5+6)	-434.52	-204.14	228.61	-638.66	377.56
8	Tax expense					
	(a) Current Tax	19.34	47.49	69.35	66.83	110.01
	(b) Deferred Tax	46.63	41.84	61.32	88.47	100.84
		-27.29	5.65	8.03	-21.64	9.17
9	Profit/(Loss) for the period from continuing operations (7-8)	-453.87	-251.63	159.26	-705.50	267.55
10	Share of Profit/ (Loss) of Associates and Joint Ventures	3.17	2.83	3.97	6.00	4.00
11	Profit After Tax and Share of Profit/ (Loss) of Associates and Joint Ventures for the period from continuing operations (9+10)	-450.70	-248.80	163.23	-699.50	271.55
12	Profit/(loss) for the period from discontinued operations	0.00	0.00	0.00	0.00	0.00
13	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00
14	Profit/(loss) for the period from Discontinued operations (after tax)	0.00	0.00	0.00	0.00	0.00
15	Profit/ (loss) for the period (After tax)	-450.70	-248.80	163.23	-699.50	271.55
16	Other Comprehensive Income					
	(A) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to item that will not be reclassified to	0.00	0.00	0.00	0.00	0.00
	(B) (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to item that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	Other comprehensive income/(Loss)	0.00	0.00	0.00	0.00	0.00
17	Total Comprehensive Income for the period (13+14)	-450.70	-248.80	163.23	-699.50	271.55
	Net profit attributable to:					
	Owners of the holding company	-165.152	-67.825	163.23	-232.976	271.55
	Non-controlling interest	-285.548	-180.972	0.00	-466.520	0.00
	Other comprehensive income attributable to:					
	Owners of the holding company	0.00	0.00	0.00	0.00	0.00
	Non-controlling interest	0.00	0.00	0.00	0.00	0.00
	Total comprehensive income attributable to:					
	Owners of the holding company	-165.15	-67.82	163.23	-232.98	271.55
	Non-controlling interest	-285.55	-180.97	0.00	-466.52	0.00
18	Paid-up Equity Share Capital (Face Value INR 10 each)	1000.000	1000.000	1000.000	1000.000	1000.000
19	Earnings Per Equity Share of Rs. 10 each (for Continuing Operations)					
	(a) Basic - INR	-1.65	-0.68	1.63	-2.33	2.72
	(b) Diluted - INR	-1.65	-0.68	1.63	-2.33	2.72
20	Earnings Per Equity Share of Rs. 10 each (for Discontinuing Operations)					
	(a) Basic - INR	0.000	0.000	0.000	0.000	0.000
	(b) Diluted - INR	0.000	0.000	0.000	0.000	0.000
21	Earnings Per Equity Share of Rs. 10 each (for Continuing & Discontinuing Operations)					
	(a) Basic - INR	-1.65	-0.68	1.63	-2.33	2.72
	(b) Diluted - INR	-1.65	-0.68	1.63	-2.33	2.72

For, Medico Intercontinental Limited

Place:- Ahmedabad
Date:- 14/11/2025

SAMIR SHAH
MANAGING DIRECTOR
DIN:03350268



NOTES - CONSOLIDATED

1 The above unaudited consolidated financial results of the Company for the quarter and half year ended September 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 14, 2025. The above results reviewed by statutory auditors and who have expressed an unmodified opinion on these results.

2 During the quarter and half year ended September 30, 2025, the company is operating in single segment. So, segment reporting is not applicable for this quarter, but segment information shall be provided when it applicable.

3 The key standalone financial information of the Company is given below:

Particulars	Quarter ended			Half year ended		Year ended
	30/09/2025	30/06/2025	30/09/2024	30/09/2025	30/09/2024	31/03/2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Revenue from operations	1300.00	1370.86	2903.51	2670.86	4065.83	6763.75
Profit before tax	80.54	73.68	144.53	154.22	212.92	357.55
Net profit after tax	59.19	55.60	98.89	114.80	148.61	256.58
Total comprehensive income	59.19	55.60	98.89	114.80	148.61	256.58

4. During the quarter ended June 30, 2025, the Group has changed its accounting policy for investments in joint venture (MEDICO LAB). Previously, the Group accounted for joint venture using the proportionate consolidation method. Effective Q1 2025-26, the Group has adopted the equity method of accounting for investments in joint ventures, in accordance with Ind AS 28 "Investments in Associates and Joint Ventures."

The change in accounting policy has been applied retrospectively and the corresponding comparative figures for the previous periods have been restated to ensure comparability, as required under Ind AS 8 "Accounting Policies, Changes in Accounting Estimates and Errors."

This change is effective from April 01, 2025, and as a result, the Group has ceased proportionate consolidation of MEDICO LAB and now recognizes its investment as a single line item in the consolidated balance sheet and its share of profit or loss in the consolidated income statement

To reflect this change and maintain comparability, prior period figures have been restated. The table below summarizes the quantitative impact on the Group's consolidated financial statements for the year ended 31st March 2025:




Restated Comparative Figures as below

(Rs. In Lakhs)									
	Q2 FY 2024-25			Half year (Q1+Q2) FY 2024-25			FY 2024-25		
Particulars	As Previously Reported	Effect of Restatement	As Restated	As Previously Reported	Effect of Restatement	As Restated	As Previously Reported	Effect of Restatement	As Restated
Revenue	3,727.91	-76.87	3,651.04	5,563.89	26.47	5,590.36	9,637.12	-63.89	9,573.23
Expenses	3,494.15	-71.72	3,422.43	5,181.12	31.68	5,212.80	8,939.80	-48.68	8,891.12
Profit after Tax	163.23	-3.97	159.26	271.55	-4.00	267.55	505.73	-10.2	495.53
Share of Profit/(loss) from Joint Venture			3.97			4.00			10.2

In The Consolidated Balance sheet

PARTICULAR	FY 2024-25		
	AS PREVIOUSLY REPORTED	EFFECT OF RESTATEMENT	AS RESTATED
TOTAL ASSETS	7576.47	115.47	7691.94
TOTAL LIABILITIES	2711.52	-28.52	2683.00
TOTAL EQUITY	4864.95	143.99	5008.94

5. The previous period figures have been re-grouped / reclassified, wherever considered necessary, to make them comparable.

For, Medico Intercontinental Limited

Place: Ahmedabad
Date: -14/11/2025

SAMIR SHAH
MANAGING DIRECTOR
DIN: 03350268



MEDICO INTERCONTINENTAL LIMITED

CIN: L24100GJ1984PLC111413

Regd. Off: 1-5TH FLOOR, ADIT RAJ ARCADE NR KARMA SHRESHTHA TOWER, 100 FT RD, SATELLITE, Ahmedabad GJ 380015 IN

Tel No. 079-26742739 E-mail:- mail@medicointercontinental.com Website: www.medicointercontinental.com

Unaudited Consolidated Statement of Assets and Liabilities as at September 30, 2025

(Rs in Lakhs)

	Particulars	As at 30.09.2025	As at 31.03.2025
		Unaudited	Audited and Restated
A. ASSETS			
1 Non-current assets			
Property, Plant and Equipment		3,554.50	357.02
Capital work-in-progress		-	-
Investment Property		294.11	394.00
Intangible Assets		1,422.85	113.01
Financial Assets		-	-
(i) Investments		243.79	300.54
(ii) Loans		263.33	-
(iii) Other financial assets		17.31	-
Deferred tax assets (Net)		-	-
Other non-current Assets		365.20	1,047.44
Total Non-Current Assets		6,161.10	2,212.01
2 Current assets			
Inventories		1,288.30	851.73
Financial Assets		-	-
(i) Trade Receivables		3,044.85	3,232.69
(ii) Cash and Cash Equivalents		440.38	224.42
(iii) Loans		-	100.80
Other Current Assets		720.59	1,070.29
Total Current Assets		5,494.12	5,479.92
TOTAL ASSETS		11,655.22	7,691.94
B. EQUITY AND LIABILITIES			
1 Equity			
Equity Share capital		1,000.00	1,000.00
Other Equity		3,775.96	4,008.94
Share Application Money Pending Alloment		-	-
Equity attributable to shareholders of the company		4,775.96	5,008.94
Non-Controlling interest		(1,150.82)	-
Total Equity		3,625.15	
2 Liabilities			
a Non-Current Liabilities			
Financial Liabilities			
(i) Borrowings		4,601.32	1,347.25
(ii) Lease liability		-	-
(iii) Other financial liabilities		-	53.27
Long term provisions		28.43	22.77
Deferred tax liabilities (Net)		76.17	12.01
Other non-current liabilities		0.30	0.30
Total Non-current liabilities		4,706.22	1,435.60
b Current liabilities			
Financial Liabilities			
(i) Borrowings		-	-
(ii) Trade Payables		1,953.48	345.13
Due to micor enterprises and small enterprises		-	-
Due to others		67.02	151.97
(iv) Other financial liabilities		1,058.28	573.34
Other current liabilities		11.47	-
Short term provisions		162.21	99.80
Current tax liabilities(net)		0.55	1.26
Total Current liabilities		3,323.86	1,247.40
TOTAL EQUITY AND LIABILITIES		11,655.22	7,691.94

For and on behalf of Board of Directors of
MEDICO INTERCONTINENTAL LIMITED

Place:-Ahmedabad
Date:-14/11/2025

SAMIR SHAH
MANAGING DIRECTOR
DIN:03350268



MEDICO INTERCONTINENTAL LIMITED

CIN: L24100GJ1984PLC111413

Regd. Off: 1-5TH FLOOR, ADIT RAJ ARCADE NR KARMA SHRESHTHA TOWER, 100 FT RD, SATELLITE, Ahmedabad GJ 380015 IN

Tel No. 079-26742739

E-mail:- mail@medicointercontinental.com

Website: www.medicointercontinental.com

Unaudited Consolidated Cash Flow Statement for the half year ended 30 September, 2025

(Rs in Lakhs)

	PARTICULARS	Half year ended 30.09.2025 (Unaudited)	Half year ended 30.09.2024 (Unaudited & Restated)
A.	CASH FLOW FROM OPERATING ACTIVITIES :		
a)	Net Profit/ (Loss) before tax	-638.66	377.56
b)	OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	(638.66)	377.56
	Adjustments For:		
	Depreciation	257.28	28.23
	Finance cost	441.48	45.87
	Profit on Sale of Asset	-30.01	0.00
	Dividend received	-0.24	-0.24
	Interest received	-20.97	-9.88
	CASH GENERATED FROM OPERATIONS	8.87	441.55
	Adjustments for		
	Decrease/(Increase) in Inventories	178.49	379.69
	Decrease/(Increase) in Trade Receivables	159.62	-912.12
	Decrease/(Increase) in Short Term Loan and Advances	100.80	-96.47
	Decrease/(Increase) in Other Current Assets/Non Current Assets	1588.57	36.72
	Increase/(Decrease) in Provisions and Other Current Liabilities	-282.44	135.39
	Increase/(Decrease) Non- Current Financial Liabilities	-53.27	0.00
	Increase/(Decrease) in Trade Payables	-211.06	159.70
	Increase/(Decrease) Current Financial Liabilities	11.47	0.00
	CASH GENERATION FROM OPERATING ACTIVITY	1501.05	144.45
	Income tax Paid Net	(92.16)	(127.58)
	NET CASH FROM/(USED IN) OPERATING ACTIVITIES	1408.89	16.87
B.	CASH FLOW FROM INVESTING ACTIVITIES:		
	Purchase of Fixed and Intangible assets	-114.64	-187.67
	Purchase of Investment Property	-198.00	0.00
	Purchase/Sale Investments	0.00000	0.00
	Payment for Intangible Assets	315.05	0.00
	Sales Of Property	62.80	(158.02)
	Investment In Joint Venture/Associates (Net of Profit for the period)	1.05	-
	(Increase)/ Decrease in Financial Assets	-	-
	Deposits (net)	20.97	9.88
	Interest Income	0.24	0.24
	Dividend Income	87.47	-335.58
	NET CASH FROM/(USED IN) INVESTING ACTIVITIES	87.47	-335.58
C.	CASH FLOW FROM FINANCING ACTIVITIES:		
	Proceeds from Issue of Shares	-	-
	Increase/(Decrease) in Loan and Advances	0.00	0.00
	Increase/(Decrease) in other financial asset	0.00	-
	Proceed from /(Repayment) of Long Term Borrowing net	-671.28	610.76
	Proceed from /(Repayment) of Short Term Borrowing net	-226.21	-23.63
	Dividend Paid	0.00	0.00
	Finance Costs paid	-441.48	-45.87
	NET CASH FROM/(USED IN) FINANCING ACTIVITIES	-1338.97	541.25
	NET INCREASE IN CASH AND CASH EQUIVALENTS	157.40	222.55
	CASH AND CASH EQUIVALENTS (At the beginning of the year)	282.98	336.52
	CASH AND CASH EQUIVALENTS (At the end of the year)	440.38	559.07

For and on behalf of Board of Directors of
MEDICO INTERCONTINENTAL LIMITED

Place:-Ahmedabad
Date:-14/11/2025


SAMIR SHAH
MANAGING DIRECTOR
DIN:03350268

